0 5 Kappa Kappa NNP 6 16 B-specific b-specific JJ 17 20 DNA DNA NNP 21 28 binding binding NN 29 37 proteins protein NNS 38 41 are be VBP 42 56 differentially differentially RB 57 66 inhibited inhibit VBN 67 69 by by IN 70 78 enhancer enhancer NN 79 88 mutations mutation NNS 89 92 and and CC 93 103 biological biological JJ 104 113 oxidation oxidation NN 113 114 . . . 116 121 Kappa Kappa NNP 122 123 B B NNP 124 125 ( ( ( 125 130 kappa kappa NNP 131 132 B B NNP 132 133 ) ) ) 134 142 enhancer enhancer NN 143 150 binding binding NN 151 159 proteins protein NNS 160 168 isolated isolate VBN 169 173 from from IN 174 177 the the DT 178 184 nuclei nucleus NNS 185 187 of of IN 188 197 activated activate VBN 198 203 human human JJ 204 205 T t NN 206 211 cells cell NNS 212 219 produce produce VBP 220 223 two two CD 224 232 distinct distinct JJ 233 246 nucleoprotein nucleoprotein NN 247 256 complexes complex NNS 257 261 when when WRB 262 271 incubated incubate VBN 272 276 with with IN 277 280 the the DT 281 286 kappa kappa NN 287 288 B B NNP 289 296 element element NN 297 301 from from IN 302 305 the the DT 306 319 interleukin-2 interleukin-2 NN 320 334 receptor-alpha receptor-alpha NN 335 336 ( ( ( 336 341 IL-2R IL-2R NNP 342 347 alpha alpha NN 347 348 ) ) ) 349 353 gene gene NN 353 354 . . . 355 360 These these DT 361 364 two two CD 365 376 DNA-protein dna-protein JJ 377 386 complexes complex NNS 387 390 are be VBP 391 399 composed compose VBN 400 402 of of IN 403 405 at at IN 406 411 least least JJS 412 416 four four CD 417 421 host host NN 422 430 proteins protein NNS 431 432 ( ( ( 432 435 p50 p50 NN 435 436 , , , 437 440 p55 p55 NN 440 441 , , , 442 445 p75 p75 NN 445 446 , , , 447 450 p85 p85 NN 450 451 ) ) ) 451 452 , , , 453 457 each each DT 458 460 of of IN 461 466 which which WDT 467 473 shares share VBZ 474 484 structural structural JJ 485 495 similarity similarity NN 496 500 with with IN 501 504 the the DT 505 510 v-rel v-rel NN 511 519 oncogene oncogene NN 520 527 product product NN 527 528 . . . 529 536 Nuclear nuclear JJ 537 547 expression expression NN 548 550 of of IN 551 556 these these DT 557 565 proteins protein NNS 566 568 is be VBZ 569 576 induced induce VBN 577 581 with with IN 582 592 distinctly distinctly RB 593 601 biphasic biphasic JJ 602 610 kinetics kinetic NNS 611 620 following follow VBG 621 628 phorbol phorbol NN 629 634 ester ester NN 635 645 activation activation NN 646 648 of of IN 649 650 T t NN 651 656 cells cell NNS 657 658 ( ( ( 658 665 p55/p75 p55/p75 NN 666 671 early early JJ 672 675 and and CC 676 683 p50/p85 p50/p85 NN 684 688 late late RB 688 689 ) ) ) 689 690 . . . 691 702 DNA-protein dna-protein JJ 703 715 crosslinking crosslinking NN 716 723 studies study NNS 724 728 have have VBP 729 737 revealed reveal VBN 738 742 that that IN 743 746 the the DT 747 751 more more RBR 752 759 rapidly rapidly RB 760 769 migrating migrate VBG 770 772 B2 b2 NN 773 780 complex complex NN 781 789 contains contain VBZ 790 794 both both CC 795 798 p50 p50 NN 799 802 and and CC 803 806 p55 p55 NN 807 812 while while IN 813 816 the the DT 817 821 more more RBR 822 828 slowly slowly RB 829 838 migrating migrate VBG 839 841 B1 b1 NN 842 849 complex complex NN 850 852 is be VBZ 853 861 composed compose VBN 862 864 of of IN 865 868 p50 p50 NN 868 869 , , , 870 873 p55 p55 NN 873 874 , , , 875 878 p75 p75 NN 878 879 , , , 880 883 and and CC 884 887 p85 p85 NN 887 888 . . . 889 902 Site-directed site-directed JJ 903 914 mutagenesis mutagenesis NN 915 917 of of IN 918 921 the the DT 922 931 wild-type wild-type JJ 932 937 IL-2R il-2r NN 938 943 alpha alpha NN 944 949 kappa kappa NN 950 951 B B NNP 952 960 enhancer enhancer NN 961 962 ( ( ( 962 974 GGGGAATCTCCC GGGGAATCTCCC NNP 974 975 ) ) ) 976 979 has have VBZ 980 988 revealed reveal VBN 989 993 that that IN 994 997 the the DT 998 1005 binding binding NN 1006 1008 of of IN 1009 1012 p50 p50 NN 1013 1016 and and CC 1017 1020 p55 p55 NN 1021 1022 ( ( ( 1022 1024 B2 b2 NN 1025 1032 complex complex NN 1032 1033 ) ) ) 1034 1036 is be VBZ 1037 1049 particularly particularly RB 1050 1059 sensitive sensitive JJ 1060 1062 to to TO 1063 1073 alteration alteration NN 1074 1076 of of IN 1077 1080 the the DT 1081 1082 5 5 CD 1082 1083 ’ ' SYM 1084 1091 triplet triplet NN 1092 1094 of of IN 1095 1109 deoxyguanosine deoxyguanosine NN 1110 1118 residues residue NNS 1118 1119 . . . 1120 1122 In in IN 1123 1131 contrast contrast NN 1131 1132 , , , 1133 1142 formation formation NN 1143 1145 of of IN 1146 1149 the the DT 1150 1152 B1 b1 NN 1153 1160 complex complex NN 1160 1161 , , , 1162 1172 reflecting reflect VBG 1173 1176 the the DT 1177 1184 binding binding NN 1185 1187 of of IN 1188 1191 p75 p75 NN 1192 1195 and and CC 1196 1199 p85 p85 NN 1199 1200 , , , 1201 1211 critically critically RB 1212 1219 depends depend VBZ 1220 1224 upon upon IN 1225 1228 the the DT 1229 1233 more more JJR 1234 1235 3 3 CD 1235 1236 ’ ' SYM 1237 1246 sequences sequence NNS 1247 1249 of of IN 1250 1254 this this DT 1255 1263 enhancer enhancer NN 1264 1271 element element NN 1271 1272 . . . 1273 1276 DNA DNA NNP 1277 1284 binding binding NN 1285 1287 by by IN 1288 1291 all all DT 1292 1296 four four CD 1297 1299 of of IN 1300 1305 these these DT 1306 1317 Rel-related rel-related JJ 1318 1325 factors factor NNS 1326 1328 is be VBZ 1329 1336 blocked block VBN 1337 1339 by by IN 1340 1349 selective selective JJ 1350 1358 chemical chemical JJ 1359 1371 modification modification NN 1372 1374 of of IN 1375 1381 lysine lysine NN 1382 1385 and and CC 1386 1394 arginine arginine NN 1395 1403 residues residue NNS 1403 1404 , , , 1405 1415 suggesting suggest VBG 1416 1420 that that IN 1421 1425 both both DT 1426 1428 of of IN 1429 1434 these these DT 1435 1440 basic basic JJ 1441 1446 amino amino NN 1447 1452 acids acid NNS 1453 1456 are be VBP 1457 1465 required require VBN 1466 1469 for for IN 1470 1477 binding bind VBG 1478 1480 to to TO 1481 1484 the the DT 1485 1490 kappa kappa NN 1491 1492 B B NNP 1493 1500 element element NN 1500 1501 . . . 1502 1511 Similarly similarly RB 1511 1512 , , , 1513 1521 covalent covalent JJ 1522 1534 modification modification NN 1535 1537 of of IN 1538 1542 free free JJ 1543 1553 sulfhydryl sulfhydryl NN 1554 1560 groups group NNS 1561 1565 with with IN 1566 1573 diamide diamide NN 1574 1575 ( ( ( 1575 1585 reversible reversible JJ 1585 1586 ) ) ) 1587 1589 or or CC 1590 1606 N-ethylmaleimide N-ethylmaleimide NNP 1607 1608 ( ( ( 1608 1620 irreversible irreversible JJ 1620 1621 ) ) ) 1622 1629 results result VBZ 1630 1632 in in IN 1633 1634 a a DT 1635 1643 complete complete JJ 1644 1648 loss loss NN 1649 1651 of of IN 1652 1655 DNA DNA NNP 1656 1663 binding binding NN 1664 1672 activity activity NN 1672 1673 . . . 1674 1676 In in IN 1677 1685 contrast contrast NN 1685 1686 , , , 1687 1691 mild mild JJ 1692 1701 oxidation oxidation NN 1702 1706 with with IN 1707 1714 glucose glucose NN 1715 1722 oxidase oxidase NN 1723 1734 selectively selectively RB 1735 1743 inhibits inhibit VBZ 1744 1747 p75 p75 NN 1748 1751 and and CC 1752 1755 p85 p85 NN 1756 1763 binding binding NN 1764 1769 while while IN 1770 1773 not not RB 1774 1782 blocking block VBG 1783 1786 p50 p50 NN 1787 1790 and and CC 1791 1794 p55 p55 NN 1795 1807 interactions interaction NNS 1807 1808 . . . 1809 1814 These these DT 1815 1823 findings finding NNS 1824 1831 suggest suggest VBP 1832 1836 that that IN 1837 1844 reduced reduce VBN 1845 1853 cysteine cysteine NN 1854 1860 thiols thiol NNS 1861 1865 play play VBP 1866 1868 an an DT 1869 1878 important important JJ 1879 1883 role role NN 1884 1886 in in IN 1887 1890 the the DT 1891 1894 DNA dna NN 1895 1902 binding binding NN 1903 1911 activity activity NN 1912 1914 of of IN 1915 1919 this this DT 1920 1926 family family NN 1927 1929 of of IN 1930 1941 Rel-related rel-related JJ 1942 1955 transcription transcription NN 1956 1963 factors factor NNS 1963 1964 . . .